IDHIFA ® (enasidenib) tablets, for oral use
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in
the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and
may not reflect the rates observed in practice.
The following is a Brief Summary; refer to full Prescribing Information for complete product information.
WARNING: DIFFERENTIATION SYNDROME
Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be
fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary
infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy,
bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected,
initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings
and Precautions (5.1) and Adverse Reactions (6.1)].
The safety evaluation of single-agent IDHIFA is based on 214 patients with relapsed or refractory AML
who were assigned to receive 100 mg daily. The median duration of exposure to IDHIFA was 4.3 months
(range 0.3 to 23.6). The 30-day and 60-day mortality rates observed with IDHIFA were 4.2% (9/214) and
11.7% (25/214), respectively.
The most common adverse reactions (≥20%) of any grade were nausea, vomiting, diarrhea, elevated
bilirubin and decreased appetite.
Serious adverse reactions were reported in 77.1% of patients. The most frequent serious adverse
reactions (≥2%) were leukocytosis (10%), diarrhea (6%), nausea (5%), vomiting (3%), decreased
appetite (3%), tumor lysis syndrome (5%), and differentiation syndrome (8%). Differentiation syndrome
events characterized as serious included pyrexia, renal failure acute, hypoxia, respiratory failure, and
multi-organ failure.
1 INDICATIONS AND USAGE
1.1 Acute Myeloid Leukemia
IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia
(AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
2 DOSAGE AND ADMINISTRATION
2.1 Patient Selection
Select patients for the treatment of AML with IDHIFA based on the presence of IDH2 mutations in the
blood or bone marrow [see Indications and Usage (1.1)]. Information on FDA-approved tests for the
detection of IDH2 mutations in AML is available at http://www.fda.gov/CompanionDiagnostics.
Overall, 92 of 214 patients (43%) required a dose interruption due to an adverse reaction; the most
common adverse reactions leading to dose interruption were differentiation syndrome (4%) and
leukocytosis (3%). Ten of 214 patients (5%) required a dose reduction due to an adverse reaction; no
adverse reaction required dose reduction in more than 2 patients. Thirty-six of 214 patients (17%)
permanently discontinued IDHIFA due to an adverse reaction; the most common adverse reaction leading
to permanent discontinuation was leukocytosis (1%).
2.2 Recommended Dosage
The recommended starting dose of IDHIFA is 100 mg taken orally once daily with or without food until
disease progression or unacceptable toxicity. For patients without disease progression or unacceptable
toxicity, treat for a minimum of 6 months to allow time for clinical response.
Adverse reactions reported in the trial are shown in Table 2.
Table 2: Adverse Reactions Reported in ≥10% (Any Grade) or ≥3% (Grade 3-5)
of Patients with Relapsed or Refractory AML
Do not split or crush IDHIFA tablets. Administer IDHIFA tablets orally about the same time each day. If a
dose of IDHIFA is vomited, missed, or not taken at the usual time, administer the dose as soon as
possible on the same day, and return to the normal schedule the following day.
IDHIFA (100 mg daily)
N=214
2.3 Monitoring and Dosage Modifications for Toxicities
Assess blood counts and blood chemistries for leukocytosis and tumor lysis syndrome prior to the
initiation of IDHIFA and monitor at a minimum of every 2 weeks for at least the first 3 months during
treatment. Manage any abnormalities promptly [see Adverse Reactions (6.1)].
Body System
Adverse Reaction
Table 1: Dosage Modifications for IDHIFA-Related Toxicities
Recommended Action
• Differentiation syndrome • If differentiation syndrome is suspected, administer
systemic corticosteroids and initiate hemodynamic
monitoring [see Warnings and Precautions (5.1)].
• Elevation of bilirubin greater than 3 times
• Reduce IDHIFA dose to 50 mg daily.
the upper limit of normal (ULN) sustained
• Resume IDHIFA at 100 mg daily if bilirubin elevation
for ≥2 weeks without elevated transaminases
resolves to less than 2 x ULN.
or other hepatic disorders
107 (50) 11 (5)
Diarrhea 91 (43) 17 (8)
Vomiting 73 (34) 4 (2)
Decreased appetite 73 (34) 9 (4)
Tumor lysis syndrome b 13 (6) 12 (6)
Differentiation syndrome c 29 (14) 15 (7)
Noninfectious leukocytosis 26 (12) 12 (6)
25 (12) 0 (0)
Blood and Lymphatic System Disorders
• Resume IDHIFA when signs and symptoms improve to
Grade 2* or lower.
• Interrupt IDHIFA if leukocytosis is not improved with
hydroxyurea, and then resume IDHIFA at 100 mg daily
when WBC is less than 30 x 10 9 /L.
Nausea
Metabolism and Nutrition Disorders
• Interrupt IDHIFA if severe pulmonary symptoms requiring
intubation or ventilator support, and/or renal dysfunction
persist for more than 48 hours after initiation of
corticosteroids [see Warnings and Precautions (5.1)].
• Noninfectious leukocytosis (white blood cell • Initiate treatment with hydroxyurea, as per standard
[WBC] count greater than 30 x 10 9 /L)
institutional practices.
≥Grade 3
N=214
n (%)
Gastrointestinal Disorders a
Interrupt dosing or reduce dose for toxicities. See Table 1 for dosage modification guidelines.
Adverse Reaction All Grades
N=214
n (%)
Nervous System Disorders
Dysgeusia
Gastrointestinal disorders observed with IDHIFA treatment can be associated with other commonly
reported events such as abdominal pain, and weight decreased.
b
Tumor lysis syndrome observed with IDHIFA treatment can be associated with commonly reported uric
acid increased.
c
Differentiation syndrome can be associated with other commonly reported events such as respiratory
failure, dyspnea, hypoxia, pyrexia, peripheral edema, rash, or renal insufficiency.
a
Other clinically significant adverse reactions occurring in ≤10% of patients included:
Respiratory, Thoracic, and Mediastinal Disorders: Pulmonary edema, acute respiratory distress
syndrome
• Other Grade 3* or higher toxicity considered • Interrupt IDHIFA until toxicity resolves to Grade 2* or
related to treatment including tumor lysis
lower.
syndrome
• Resume IDHIFA at 50 mg daily; may increase to 100 mg
daily if toxicities resolve to Grade 1* or lower.
Changes in selected post-baseline laboratory values that were observed in patients with relapsed or
refractory AML are shown in Table 3.
Table 3: Most Common (≥20%) New or Worsening Laboratory Abnormalities
Reported in Patients with Relapsed or Refractory AML
• If Grade 3* or higher toxicity recurs, discontinue IDHIFA.
IDHIFA (100 mg daily)
N=214
*Grade 1 is mild, Grade 2 is moderate, Grade 3 is serious, Grade 4 is life-threatening.
Parameter a
4 CONTRAINDICATIONS
None.
5 WARNINGS AND PRECAUTIONS
5.1 Differentiation Syndrome
In the clinical trial, 14% of patients treated with IDHIFA experienced differentiation syndrome, which may
be life-threatening or fatal if not treated. Differentiation syndrome is associated with rapid proliferation
and differentiation of myeloid cells. While there is no diagnostic test for differentiation syndrome,
symptoms in patients treated with IDHIFA included acute respiratory distress represented by dyspnea
and/or hypoxia (68%) and need for supplemental oxygen (76%); pulmonary infiltrates (73%) and pleural
effusion (45%); renal impairment (70%); fever (36%); lymphadenopathy (33%); bone pain (27%);
peripheral edema with rapid weight gain (21%); and pericardial effusion (18%). Hepatic, renal, and
multi-organ dysfunction have also been observed. Differentiation syndrome has been observed with and
without concomitant hyperleukocytosis, and as early as 10 days and at up to 5 months after IDHIFA
initiation.
If differentiation syndrome is suspected, initiate oral or intravenous corticosteroids (e.g., dexamethasone
10 mg every 12 hours) and hemodynamic monitoring until improvement. Taper corticosteroids only after
resolution of symptoms. Symptoms of differentiation syndrome may recur with premature discontinuation
of corticosteroid treatment. If severe pulmonary symptoms requiring intubation or ventilator support,
and/or renal dysfunction persist for more than 48 hours after initiation of corticosteroids, interrupt IDHIFA
until signs and symptoms are no longer severe [see Dosage and Administration (2.3)]. Hospitalization
for close observation and monitoring of patients with pulmonary and/or renal manifestation is
recommended.
5.2 Embryo-Fetal Toxicity
Based on animal embryo-fetal toxicity studies, IDHIFA can cause embryo-fetal harm when administered
to a pregnant woman. In animal embryo-fetal toxicity studies, enasidenib caused embryo-fetal toxicities
starting at 0.1 times the steady state clinical exposure based on the area under the concentration-time
curve (AUC) at the recommended human dose. Advise females of reproductive potential to use effective
contraception during treatment with IDHIFA and for at least 1 month after the last dose of IDHIFA. Advise
males with female partners of reproductive potential to use effective contraception during treatment with
IDHIFA and for at least 1 month after the last dose of IDHIFA. Pregnant women, patients becoming
pregnant while receiving IDHIFA, or male patients with pregnant female partners should be apprised of
the potential risk to the fetus [see Use in Specific Populations (8.1, 8.3)].
6 ADVERSE REACTIONS
The following serious adverse reactions are described elsewhere in the labeling:
• Differentiation Syndrome [see Warnings and Precautions (5.1)]
a
All Grades
(%) Grade ≥3
(%)
Total bilirubin increased 81 15
Calcium decreased 74 8
Potassium decreased 41 15
Phosphorus decreased 27 8
Includes abnormalities occurring up to 28 days after last IDHIFA dose, if new or worsened by at least one
grade from baseline, or if baseline was unknown. The denominator varies based on data collected for each
parameter (N=213 except phosphorous N=209).
Elevated Bilirubin
IDHIFA may interfere with bilirubin metabolism through inhibition of UGT1A1. Thirty-seven percent of
patients (80/214) experienced total bilirubin elevations ≥2 x ULN at least one time. Of those patients who
experienced total bilirubin elevations ≥2 x ULN, 35% had elevations within the first month of treatment,
and 89% had no concomitant elevation of transaminases or other severe adverse events related to liver
disorders. No patients required a dose reduction for hyperbilirubinemia; treatment was interrupted in
3.7% of patients, for a median of 6 days. Three patients (1.4%) discontinued IDHIFA permanently due to
hyperbilirubinemia.
Noninfectious Leukocytosis
IDHIFA can induce myeloid proliferation resulting in a rapid increase in white blood cell count.
Tumor Lysis Syndrome
IDHIFA can induce myeloid proliferation resulting in a rapid reduction in tumor cells which may pose a
risk for tumor lysis syndrome.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Based on animal embryo-fetal toxicity studies, IDHIFA can cause fetal harm when administered to a
pregnant woman. There are no available data on IDHIFA use in pregnant women to inform a drug-
associated risk of major birth defects and miscarriage. In animal embryo-fetal toxicity studies, oral
administration of enasidenib to pregnant rats and rabbits during organogenesis was associated with
embryo-fetal mortality and alterations to growth starting at 0.1 times the steady state clinical exposure
based on the AUC at the recommended human dose (see Data). If this drug is used during pregnancy, or
if the patient becomes pregnant while taking this drug, advise the patient of the potential risk to a fetus.